OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012 · tracked via the Priya Life Science USA tracker

Sponsor

Amgen

Phase

Phase 3

Started

2025-08-22

Last updated

2026-08-21

Condition(s) studied

Cardiovascular Disease

Investigational drug(s) / intervention(s)

OlpasiranPlacebo

Olpasiran: Olpasiran will be administered via SC injection.

Placebo: Placebo will be administered via SC injection.

Study summary

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Eligibility

Sex

ALL

Min age

50 Years

Max age

105 Years

Healthy volunteers

Inclusion Criteria: * Age ≥50 years * Lp(a)≥ 200 nmol/L during screening * Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis Exclusion Criteria: * Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia) * Prior or planned arterial revascularization * History of major bleeding disorder

Primary outcome measure(s)

Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First — Up to approximately 6.2 years

Trial sites (252)

Facility	City	Region	Status
Advanced Cardiovascular LLC	Alexander City	Alabama	Recruiting
University of Alabama Birmingham Saint Vincents Birmingham	Birmingham	Alabama	Recruiting
Birmingham Clinical Research	Birmingham	Alabama	Recruiting
Alliance For Multispecialty Research - Daphne	Daphne	Alabama	Recruiting
Eastern Shore Research Institute	Fairhope	Alabama	Recruiting
Heart Center Research LLC	Huntsville	Alabama	Recruiting
CB Flock Research Corporation	Mobile	Alabama	Recruiting
Phoenix Clinical	Phoenix	Arizona	Recruiting
Elite Clinical Studies LLC	Phoenix	Arizona	Recruiting
Hero Clinical Research	Phoenix	Arizona	Recruiting
HonorHealth Research Institute	Scottsdale	Arizona	Recruiting
Eclipse Clinical Research	Tucson	Arizona	Recruiting
Lynn Institute of the Ozarks	Little Rock	Arkansas	Recruiting
National Heart Institute	Beverly Hills	California	Recruiting
310 Clinical Research	Inglewood	California	Recruiting
University of California San Diego	La Jolla	California	Recruiting
InvivoCure	Los Angeles	California	Recruiting
Valley Clinical Trials	Northridge	California	Recruiting
Clinical Trials Research - Sacramento	Roseville	California	Recruiting
Alliance Clinical Research	San Diego	California	Recruiting
Encompass Clinical Research	Spring Valley	California	Recruiting
Stanford Health Care	Stanford	California	Recruiting
Manshadi Heart Institute	Stockton	California	Recruiting
Blue Coast Cardiology	Vista	California	Recruiting
Diablo Clinical Research	Walnut Creek	California	Recruiting
Focus Clinical Research	West Hills	California	Recruiting
Interventional Cardiology Medical Group	West Hills	California	Recruiting
UCHealth Memorial Central	Colorado Springs	Colorado	Recruiting
South Denver Cardiology Associates	Littleton	Colorado	Recruiting
Gandelman Cardiology, PC	Greenwich	Connecticut	Recruiting
ClinTrial Hamden	Hamden	Connecticut	Recruiting
Chase Medical Research LLC	Waterbury	Connecticut	Recruiting
Excel Medical Clinical Trials	Boca Raton	Florida	Recruiting
Clearwater Cardiovascular Consultants	Clearwater	Florida	Recruiting
Proactive Clinical Research	Fort Lauderdale	Florida	Terminated
Elite Cardiac Research Center LLC	Hialeah	Florida	Terminated
Jacksonville Center for Clinical Research	Jacksonville	Florida	Recruiting
East Coast Institute for Research, LLC	Lake City	Florida	Recruiting
Columbus Clinical Services LLC	Miami	Florida	Recruiting
Kendall South Medical Center	Miami	Florida	Recruiting

+ 212 more sites — see the full list on the official registry below.

More Amgen trials in the USA

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) Recruiting

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta Active, not recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity Recruiting

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Starting soon

Other trials for the same condition

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Starting soon

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial Recruiting

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction Active, not recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event Recruiting

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07136012 on ClinicalTrials.gov ↗ ← All trials in the USA